Report Scope: The scope of this report is broad and covers type, production method, technology and applications of radiopharmaceuticals and therapeutics.By type, the market has been segmented into radiotherapy and radiopharmaceuticals.
Revenue forecasts from 2017 to 2023 are provided for each segment and regional market, with estimated values derived from manufacturers’ total revenues.
The report also includes a discussion of the major players in each region in the radiopharmaceutical and therapeutics market. Further, it explains the major drivers and regional dynamics of the global radiopharmaceutical and therapeutics market and current trends within the industry.
The report concludes with a special focus on the vendor landscape and detailed profiles of the major vendors in this market.
Report Includes: - 94 data tables and 83 additional tables - An overview of the global market for radiotherapy, radiopharmaceuticals and nuclear medicines - Examination of present and future strategies within the radiopharmaceuticals market, including radiopharmaceuticals for both diagnostic and therapeutic purposes - Detailed description of positron emission tomography (PET) and single photon emission computed tomography (SPECT) and discussion of their applications - Evaluation of market opportunities for external beam radiation therapy, internal radiation therapy and systemic radiotherapy - Coverage of new products launches and product enhancement in the industry - Comprehensive company profiles of major players, including Accuray Inc., Bayer Pharma AG, C. R. Bard Inc., Eli Lilly and Company, Navidea Biopharmaceuticals Inc., Siemens Healthcare, and Triad Isotopes Inc.
Summary Population and human life expectancy are growing globally, spurring more chronic conditions and lifethreatening diseases.Obesity, a sedentary lifestyle and a lack of physical activity have further worsened the situation, leading to the increased importance of medical interventions and treatments.
Despite incredible advancements in the field of medicine in the last few decades, an unmet need remains for the prevention, diagnosis and treatment of aggressive ailments such as cancer, cardiovascular diseases and central nervous system disorders.
Since the discovery of radioactivity, it has been recognized that radiation can play a role in the treatment of various diseases.Radiopharmaceuticals are a type of radioactive drug that is internally administered and intended for use in the diagnosis and treatment of diseases.
Radiopharmaceuticals are now a crucial part of the healthcare industry, as they can identify various disease processes much earlier than other diagnostic tests.Applications of radiopharmaceuticals are growing significantly in the fields of cardiology, neurology, oncology and other medical specialties such as endocrinology, gastroenterology and nephrology, for both diagnostic and therapeutic purposes.
Radiopharmaceuticals have also become an inevitable part of personalized medicine.Diagnostic applications account for morethan an REDACTED share of the global radiopharmaceutical market, and therapeutic applications constitutethe smaller part of the market.
The market for therapeutic radiopharmaceuticals is expected to grow atsteep rate in the coming years, due to growing applications and increased demand.
Growing acceptance and utilization of nuclear medicine scans (i.e., SPECT and PET) and better availability of radiopharmaceuticals due to an increasing number of cyclotrons have significantly contributed to growth in the radiopharmaceutical industry. Innovative technological equipment leading to early and accurate diagnoses, increased awareness of radiopharmaceuticals among physicians and patients and new regulatory approvals of radiopharmaceuticals are other major driving forces for the global radiopharmaceutical market. Furthermore, increasing incidences of different types of cancers across the globe are considered a major driver behind the growth of radiopharmaceuticals and therapeutics. According to Our World in Data, approximately 19 million people had cancer in 1990; that has increased more than two-fold as of 2016, reaching 42 million worldwide. In addition, breast cancer has been identified as the leading type of cancer, as eight million people had breast cancer in 2016. In the same year, 6.3 million, 5.7 million and 2.8 million people had colon and rectum cancer, prostate cancer and tracheal, bronchus and lung cancer, respectively. Hence, the increasing incidences of various cancers drives the need for radiopharmaceuticals and therapeutics, considering diagnostic and therapeutic areas.
The global radiopharmaceutical and therapeutics market is projected to rise at a CAGR of REDACTED during the forecast period of 2018 through 2023. In 2023, total revenues are expected to reach more than REDACTED, an increase of REDACTED from the REDACTED in revenue in 2017.
Our reports have been used by over 10K customers, including:
Dyslipidemia - Pipeline Review, H2 2019 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H2 2019, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape. Dyslipidemia is defined as elevation of the total cholesterol,...
Pruritus - Pipeline Review, H2 2019 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Pruritus - Pipeline Review, H2 2019, provides an overview of the Pruritus (Dermatology) pipeline landscape. Pruritus, or itch, is defined as an unpleasant sensation that provokes the...
Contact Dermatitis - Pipeline Review, H2 2019 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Contact Dermatitis - Pipeline Review, H2 2019, provides an overview of the Contact Dermatitis (Dermatology) pipeline landscape. Contact dermatitis is a type of skin inflammation...
West Nile Virus Infections - Pipeline Review, H2 2019 Summary The latest Pharmaceutical and Healthcare disease pipeline guide West Nile Virus Infections - Pipeline Review, H2 2019, provides an overview of the West Nile Virus Infections (Infectious Disease) pipeline landscape. West Nile infection...
Global Genetic Disorders Partnering 2014 to 2019 provides the full collection of Genetic Disorders disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Genetic Disorders partnering deals Financial deal terms for headline, upfront and royalty by stage of development Genetic...
C5a Anaphylatoxin Chemotactic Receptor 1 - Pipeline Review, H2 2019 Summary C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Complement component 5a receptor 1 (C5AR1) or CD88 is a G protein-coupled receptor for C5a. It functions as a complement receptor. Receptor activation stimulates...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.